P J Carder

Summary

Country: UK

Publications

  1. ncbi Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast
    P J Carder
    Department of Pathology, St James s University Hospital, Leeds, UK
    Histopathology 46:320-7. 2005
  2. ncbi Surgical excision is warranted following a core biopsy diagnosis of mucocoele-like lesion of the breast
    P J Carder
    Department of Pathology, St James s University Hospital, Leeds, UK
    Histopathology 45:148-54. 2004
  3. ncbi Will the spectrum of lesions prompting a "B3" breast core biopsy increase the benign biopsy rate?
    P J Carder
    Department of Pathology, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    J Clin Pathol 56:133-8. 2003
  4. ncbi Large volume "mammotome" biopsy may reduce the need for diagnostic surgery in papillary lesions of the breast
    P J Carder
    Department of Pathology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford Royal Infirmary, Bradford, UK
    J Clin Pathol 61:928-33. 2008
  5. ncbi Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling?
    G P Skliris
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Clinical Sciences Building, Leeds, LS9 7TF
    Br J Cancer 84:1095-8. 2001
  6. ncbi Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
    J Adams
    Imperial Cancer Research Fund Cancer Medicine Research Unit, St James s University Hospital, Leeds, United Kingdom
    Cancer Res 60:2898-905. 2000
  7. ncbi Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue
    G P Skliris
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    J Pathol 197:155-62. 2002
  8. ncbi Distinct expression patterns of ER alpha and ER beta in normal human mammary gland
    V Speirs
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Leeds LS9 7TF, UK
    J Clin Pathol 55:371-4. 2002
  9. ncbi Examination of breast needle core biopsy specimens performed for screen-detected microcalcification
    V Kumaraswamy
    Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK
    J Clin Pathol 60:681-4. 2007
  10. ncbi A little bit more on the slide
    P J Carder
    J Clin Pathol 56:720. 2003

Collaborators

  • J C Liston
  • Valerie Speirs
  • R E Banks
  • KKN Namboodri
  • G P Skliris
  • V Kumaraswamy
  • Z Z R Hamady
  • S Littleford
  • J A Walker
  • J Adams
  • T G Brennan
  • J L Limer
  • S E Burdall
  • A T Parkes
  • M R Lansdown
  • K MacLennan
  • P J Selby
  • V Allgar
  • F Cairnduff
  • J J Walker
  • M A Forbes
  • R Bicknell
  • S Kaufman
  • S Hallam
  • T J Perren
  • M Lansdown
  • S Downey

Detail Information

Publications15

  1. ncbi Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast
    P J Carder
    Department of Pathology, St James s University Hospital, Leeds, UK
    Histopathology 46:320-7. 2005
    ..The appropriate management of non-malignant papillary breast lesions detected on needle core biopsy (NCB) is currently uncertain...
  2. ncbi Surgical excision is warranted following a core biopsy diagnosis of mucocoele-like lesion of the breast
    P J Carder
    Department of Pathology, St James s University Hospital, Leeds, UK
    Histopathology 45:148-54. 2004
    ....
  3. ncbi Will the spectrum of lesions prompting a "B3" breast core biopsy increase the benign biopsy rate?
    P J Carder
    Department of Pathology, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    J Clin Pathol 56:133-8. 2003
    ....
  4. ncbi Large volume "mammotome" biopsy may reduce the need for diagnostic surgery in papillary lesions of the breast
    P J Carder
    Department of Pathology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford Royal Infirmary, Bradford, UK
    J Clin Pathol 61:928-33. 2008
    ..The development of large volume "mammotome" biopsy now permits non-operative removal. Few studies have assessed the usefulness of this approach...
  5. ncbi Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling?
    G P Skliris
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Clinical Sciences Building, Leeds, LS9 7TF
    Br J Cancer 84:1095-8. 2001
    ..Here, we demonstrate for the first time, immunohistochemical detection of ERbeta in archival breast tumours...
  6. ncbi Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
    J Adams
    Imperial Cancer Research Fund Cancer Medicine Research Unit, St James s University Hospital, Leeds, United Kingdom
    Cancer Res 60:2898-905. 2000
    ..MVD correlated with tumor size. Tamoxifen-induced increases in VEGF may be important in clinical prognosis or associated pathologies...
  7. ncbi Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue
    G P Skliris
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    J Pathol 197:155-62. 2002
    ..However, there is considerable variation between the specificity and application of these antibodies, highlighting the fact that careful optimization is required when selecting an antibody for use in a particular laboratory technique...
  8. ncbi Distinct expression patterns of ER alpha and ER beta in normal human mammary gland
    V Speirs
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Leeds LS9 7TF, UK
    J Clin Pathol 55:371-4. 2002
    ..The aim of this study was to compare the cellular distribution of ER alpha and ER beta in normal human mammary gland...
  9. ncbi Examination of breast needle core biopsy specimens performed for screen-detected microcalcification
    V Kumaraswamy
    Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK
    J Clin Pathol 60:681-4. 2007
    ....
  10. ncbi A little bit more on the slide
    P J Carder
    J Clin Pathol 56:720. 2003
  11. ncbi Utility of immunohistochemistry for CD99 in the identification of matrix-producing carcinoma of the breast
    J A Walker
    Histopathology 42:300-1. 2003
  12. ncbi Oestrogen receptor beta: how should we measure this?
    V Speirs
    Br J Cancer 87:687; author reply 688-9. 2002
  13. ncbi Expression of prostate specific antigen in male breast cancer
    P J Carder
    J Clin Pathol 58:69-71. 2005
    ..Focal expression of PSA was found in one of 11 cases of male breast cancer. These results indicate that PSA should be used with caution in this context...
  14. ncbi Atypical ductal hyperplasia in male breast tissue with gynaecomastia
    Z Z R Hamady
    Histopathology 47:111-2. 2005
  15. ncbi Measurement of whole tumour size in breast cancer specimens
    S Littleford
    Histopathology 47:543-4. 2005